Medincell to Present Data Showing Improved Potential of a Monoclonal Antibody Against Melanoma Tumors Using BEPO® Technology – 07/01/2024 at 5:45 p.m.

Medincell will present its R&D advances based on its long-acting injectable technologies at the CRS 2024 conference, taking place July 8-12 in Bologna, Italy, including:

• Oncology: presentation of in vivo data illustrating the improvement of the immunomodulatory potential of a monoclonal antibody targeting tumors in melanoma via peritumoral administration with BEPO® technology

• Presentation of BEPO® STAR: new long-acting injectable technology from Medincell aimed at improving the controlled delivery of a greater number of drugs and expanding its application to new therapeutic areas

• Medincell Patented In Vitro Delivery Instrument: Presentation of an innovative in vitro device designed to accelerate formulation activities and the selection of preclinical candidates